December 2nd, 2015
Immunovia’s stock increased 60 percent on first day of trading on Nasdaq First North with a turnover of SEK 28.5 million

Trading in Immunovia AB’s shares (IMMNOV) commenced yesterday on Nasdaq First North in Stockholm. At closing the share price had surged 60 percent compared to the introduction price. The interest among investors was high. The trading turnover was SEK 28.5 million during the day, thus setting a new record among comparable First North listings during 2015.

Immunovia is a health care company based in Lund, Sweden. The company’s strategy is to decipher a large amount of information in the blood and translate it into clinically useful tools, in order to diagnose complex diseases such as cancer and to do this earlier and more accurately than previously possible. Immunovia’s core technology platform, IMMray™, is based on antibody microarray analysis. The company is currently performing clinical validation studies for commercialization of IMMray™ PanCan-d, where the ambition is to become the first blood-based test for early diagnosis of cancer of the pancreas.

“Our listing on the Nasdaq First North is a major corporate milestone for our company and a confirmation to the tremendous progress we have made over the past few years. We believe that the listing will help broaden our shareholder base, increase appeal to institutional investors, provide us with better liquidity and contribute to increasing shareholder value”, says Mats Grahn, CEO of Immunovia.

“We are committed to continue to execute on our clinical and corporate strategy, and commercialize IMMray™ PanCan-d for early diagnosis of pancreatic cancer. The test will allow clinicians worldwide to intervene much earlier in the course of this deadly cancer and thereby radically improve the patient survival rates”, Mats Grahn continues.

Advisors
Vator Securities is the financial advisor and Baker & McKenzie is the legal advisor to the Company in connection with the new share issue and listing on Nasdaq First North.

For more information, please contact:
Mats Grahn, CEO, Immunovia
Phone: + 46-70-532 02 30
E-mail: mats.grahn@immunovia.com

About Immunovia
Immunovia AB was founded in 2007 by scientists from the Department of Immunotechnology at Lund University and CREATE Health – A Strategic Centre for Translational Cancer Research in Lund, Sweden. Immunovia’s strategy is to decipher a large amount of information in the blood and translate it into clinically useful tools to diagnose complex diseases such as cancer and to do this earlier and more accurately than previously possible. Immunovia’s core technology platform, IMMray™, is based on antibody microarray analysis. The company now performs clinical validation studies for commercialization of IMMray™ PanCan-d, which has the potential to become the first blood-based test for early diagnosis of cancer of the pancreas.

Immunovia’s shares (IMMNOV) are listed on Nasdaq First North in Stockholm and Wildeco is the company’s Certified Adviser. For more information, please visit www.immunovia.com.

###